Key result
Etoricoxib reduced discontinuation due to gastrointestinal adverse events by 50% versus diclofenac, but is contraindicated in patients with ischemic heart disease or uncontrolled hypertension.
Why the study?
What is the clinical efficacy and safety profile of etoricoxib compared to traditional NSAIDs?
What is the clinical efficacy and safety profile of etoricoxib compared to traditional NSAIDs?
Etoricoxib offers improved gastrointestinal safety compared to traditional NSAIDs but carries cardiovascular and hypertensive risks, necessitating careful patient selection.
Requires individualized NSAID selection balancing GI and CV risks; leaves open head-to-head comparisons with contemporary agents.
Etoricoxib is a highly selective COX-2 inhibitor (coxib) approved in Europe for the treatment of osteoarthritis (OA), rheumatoid arthritis and acute gouty arthritis. Etoricoxib is an effective analgesic drug that has shown some improved efficacy versus traditional NSAIDs and it is the only coxib approved for the treatment of acute gouty arthritis. Moreover, recent studies evidence its efficacy in patients with ankylosing spondylitis. In the Etoricoxib Diclofenac Gastrointestinal Evaluation study performed in patients with OA, etoricoxib significantly reduced the rate of discontinuation by 50% due to gastrointestinal adverse events versus diclofenac. Comparable rates of thrombotic cardiovascular events were detected. Rates of discontinuation due to hypertension-related adverse effects were higher on etoricoxib than diclofenac. Similarly to other selective COX-2 inhibitors, etoricoxib is contraindicated in patients with ischaemic heart disease or stroke and it should be used with caution in patients with risk factors for heart disease. The European Medicines Agency has contraindicated the use of etoricoxib in patients with uncontrolled hypertension. Selective COX-2 inhibitors remain an appropriate choice in patients at low cardiovascular risk, but with increased risk of gastrointestinal complications.
No takes yet. Share an insight, caveat, or question.
Capone et al. (2005) conducted a review in Osteoarthritis, rheumatoid arthritis, and acute gouty arthritis. Etoricoxib vs. Diclofenac and traditional NSAIDs was evaluated. Etoricoxib reduced discontinuation due to gastrointestinal adverse events by 50% versus diclofenac, but is contraindicated in patients with ischemic heart disease or uncontrolled hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: